DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...

Equities research analysts at HC Wainwright lifted their Q1 2025 EPS estimates for Akero Therapeutics in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst E. Arce now ...

Y Intercept Hong Kong Ltd lessened its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 47.1% in the fourth ...

NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc.

(RTTNews) - Akero Therapeutics Inc. (AKRO) released Loss for fourth quarter that beat the Street estimates. The company's earnings totaled -$70.03 million, or -$0.99 per share. This compares with ...

Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by ...

Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed enro ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...